Premium Nahrungsergänzungsmittel | artgerecht

Abdominal Fibrosis: Causes, Symptoms & Treatment

Abdominal fibrosis is an abnormal accumulation of connective tissue in the abdominal cavity that can scar organs and impair their function over time.

Regular tips about health Regular tips about health

Things worth knowing about "Abdominal Fibrosis"

Abdominal fibrosis is an abnormal accumulation of connective tissue in the abdominal cavity that can scar organs and impair their function over time.

What is Abdominal Fibrosis?

Abdominal fibrosis (also referred to as peritoneal fibrosis or retroperitoneal fibrosis) is a condition characterized by the excessive formation and accumulation of fibrous connective tissue within the abdominal cavity. Excess collagen fibers and scar tissue build up in or around abdominal organs, the peritoneum (the lining of the abdominal cavity), or surrounding structures. This can significantly impair normal organ function and, in severe cases, lead to serious complications.

Fibrosis in general refers to the replacement of normal tissue with dense scar tissue. In the abdominal cavity, this process can affect the liver, kidneys, pancreas, intestines, and the peritoneum itself.

Causes

Abdominal fibrosis can be triggered by a variety of factors:

Chronic inflammation: Persistent inflammatory conditions such as Crohn's disease, ulcerative colitis, or chronic pancreatitis can lead to fibrosis.
Surgical procedures: Abdominal surgery can result in scar tissue formation, which may develop into extensive fibrosis known as intraperitoneal adhesions.
Infections: Bacterial or parasitic infections (e.g., peritoneal tuberculosis) can trigger fibrotic tissue development.
Radiation therapy: Radiation treatment in the abdominal area, for example during cancer therapy, can cause fibrosis as a long-term side effect.
Autoimmune diseases: Conditions such as retroperitoneal fibrosis (Ormond's disease) or systemic sclerosis affect connective tissue in the abdominal region.
Medications: Certain drugs, such as the beta-blocker methysergide, have been associated with peritoneal fibrosis.
Long-term dialysis: Patients with kidney failure undergoing peritoneal dialysis may develop encapsulating peritoneal sclerosis.

Symptoms

The symptoms of abdominal fibrosis vary depending on which structures are affected:

Chronic, often dull abdominal pain
Bloating and digestive disturbances
Nausea and vomiting
Bowel obstruction (ileus) in cases of extensive adhesions
Weight loss and loss of appetite
In liver fibrosis: fatigue, jaundice, and fluid accumulation in the abdomen (ascites)
In retroperitoneal fibrosis: back pain, urinary tract obstruction, and leg pain

Diagnosis

The diagnosis of abdominal fibrosis involves a combination of investigations:

Imaging studies: Ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) allow visualization of fibrotic zones and affected organs.
Laboratory tests: Blood count, liver and kidney function tests, and inflammatory markers (e.g., C-reactive protein) provide clues about the cause and extent of the disease.
Tissue biopsy: In some cases, a tissue sample is required to confirm the diagnosis and exclude other conditions.
Endoscopy: Gastroscopy or colonoscopy may be used to assess changes in the gastrointestinal tract.

Treatment

Treatment depends on the underlying cause, the severity, and the structures affected by fibrosis:

Medical Treatment

Corticosteroids (e.g., prednisone) are used to reduce inflammation and slow the progression of fibrosis.
Immunosuppressants such as azathioprine or mycophenolate are used in autoimmune-related cases.
Antifibrotic agents: Drugs such as pirfenidone or nintedanib, originally approved for pulmonary fibrosis, are being investigated in certain cases of abdominal fibrosis.
In retroperitoneal fibrosis, tamoxifen or colchicine may also be used.

Surgical Treatment

In cases of complications such as bowel obstruction or urinary tract obstruction, surgical intervention may be necessary. This may involve the removal of scar tissue or surgical freeing of affected structures (adhesiolysis).

Treatment of the Underlying Condition

When a treatable underlying cause is identified (e.g., an infection or chronic inflammatory bowel disease), addressing that condition is the primary goal in order to halt the progression of fibrosis.

Outlook and Prognosis

The course of abdominal fibrosis depends greatly on its cause and the timing of diagnosis. When detected early and treated appropriately, progression can often be slowed or halted. In advanced stages, however, fibrosis may lead to permanent organ damage. Regular medical follow-up is therefore essential.

References

Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. Journal of Urology, 1948.
Danford CJ, Lewis J, Zuo C et al. Peritoneal Fibrosis: Pathophysiology and Clinical Implications. Kidney International Reports, 2020.
World Health Organization (WHO): Noncommunicable Diseases - Fibrosis Overview. Available at: https://www.who.int (accessed 2024).

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.